



## Targeted Immunotherapy in Cancer

Guest Editor:

**Dr. Masakazu Kamata**

Department of Microbiology,  
Heersink School of Medicine,  
University of Alabama,  
Birmingham, AL 35294, USA

Deadline for manuscript  
submissions:

**closed (20 May 2024)**

### Message from the Guest Editor

Cancer immunotherapy is a revolutionary approach in the field of cancer treatment that harnesses the power of the immune system to fight cancer cells. It represents a significant paradigm shift from traditional cancer treatments such as surgery, chemotherapy, and radiation therapy. While cancer immunotherapy has shown remarkable success in treating certain types of cancer, it is important to acknowledge the challenges and limitations that present specifically and effectively, particularly in targeting cancer cells.

This Special Issue aims to provide a comprehensive overview of the latest advancements and emerging trends in targeted cancer immunotherapy. We welcome original research articles, reviews, and perspective articles on this theme. Topics may include, but are not limited to:

- Novel technology to deliver immunotherapeutics to target locations.
- On-off switch for CAR-T cell therapy.
- Providing cancer-targeting moiety to immunotherapeutics.
- Immunotherapy-related toxicities and management.
- Translational research in cancer immunotherapy using an advanced animal model.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)